Michael J Nemeth
Overview
Explore the profile of Michael J Nemeth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tzetzo S, Kramer E, Mohammadpour H, Kim M, Rosario S, Yu H, et al.
iScience
. 2024 Feb;
27(3):109187.
PMID: 38420590
Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic sites, yet their functional contributions to metastasis remain incompletely understood. Here, we show that alveolar macrophages (AMs), the main TRMs of...
2.
Sung P, Selvam M, Riedel S, Xie H, Bryant K, Manning B, et al.
Leukemia
. 2024 Jan;
38(2):291-301.
PMID: 38182819
Internal tandem duplication mutations in fms-like tyrosine kinase 3 (FLT3-ITD) are recurrent in acute myeloid leukemia (AML) and increase the risk of relapse. Clinical responses to FLT3 inhibitors (FLT3i) include...
3.
Colligan S, Amitrano A, Zollo R, Peresie J, Kramer E, Morreale B, et al.
J Clin Invest
. 2022 Dec;
132(23).
PMID: 36453551
While immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology, they are effective in select subsets of patients. Efficacy may be limited by tumor-driven immune suppression, of which...
4.
Oliver L, Alvarez R, Diaz R, Valdes A, Colligan S, Nemeth M, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36150744
Background: Immune suppression is common in neoplasia and a major driver is tumor-induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an untapped strategy to reverse suppression and improve...
5.
Bellusci L, Grubbs G, Srivastava P, Nemeth M, Griffiths E, Golding H, et al.
Blood
. 2022 Mar;
139(18):2842-2846.
PMID: 35344579
No abstract available.
6.
Lightman S, Peresie J, Carlson L, Holling G, Honikel M, Chavel C, et al.
Immunity
. 2021 Nov;
54(12):2772-2783.e5.
PMID: 34788602
Humoral immunity is essential for protection against pathogens, emphasized by the prevention of 2-3 million deaths worldwide annually by childhood immunizations. Long-term protective immunity is dependent on the continual production...
7.
Ngai L, Ma C, Maguire O, Do A, Robert A, Logan A, et al.
Eur J Haematol
. 2021 May;
107(3):343-353.
PMID: 34053123
Objectives: This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1...
8.
Mayer B, Nemeth K, Krepuska M, Myneni V, Maric D, Tisdale J, et al.
Clin Endocrinol (Oxf)
. 2020 Dec;
94(5):888-890.
PMID: 33314284
No abstract available.
9.
Inhibition of LSD1 in MDS progenitors restores differentiation of CD141 conventional dendritic cells
Srivastava P, Tzetzo S, Gomez E, Eng K, Jani Sait S, Kuechle J, et al.
Leukemia
. 2020 Feb;
34(9):2460-2472.
PMID: 32099035
The use of immunotherapy to treat patients with myelodysplastic syndromes (MDS) shows promise but is limited by our incomplete understanding of the immunologic milieu. In solid tumors, CD141 conventional dendritic...
10.
Twum D, Colligan S, Hoffend N, Katsuta E, Gomez E, Hensen M, et al.
JCI Insight
. 2019 Feb;
4(3).
PMID: 30728331
High macrophage infiltration in cancer is associated with reduced survival in animal models and in patients. This reflects a shift in the macrophage response from a tumor-suppressive to tumor-supportive program...